A new application for an old drug…
Renewed interest in the 2007 discussion of Dichloroacetic acid (DCA) for cancer treatment, long-used for metabolic disorders, has surfaced based on its few side effects when compared to current cancer treatments. The main proponent of studying DCA for the treatment of cancer is Dr. Evangelos Michelakis of the University of Alberta. He claims that his research has been hindered because the pharmaceutical industry does not want to fund research into a non-patentable compound.
While some may rush to judge Big Parma, Dr. Len Lichtenfeld, Deputy Chief Medical Officer for the national office of the American Cancer Society offers a more tempered view. Stating “Right now, we simply do not know what is going to occur as DCA moves through the research pipeline…It is way too soon to know whether this is a cancer treatment breakthrough or an urban legend or something in between” in his 2007 blog post < http://www.cancer.org/aspx/blog/Comments.aspx?id=130 > is perhaps the best statement to date on this drug.
In September 2007 Dr. Michelakis generated enough funding for a small phase II trial in about 50 patients < http://www.cancer.org/aspx/blog/Comments.aspx?id=130 >. For those following this story, results can be expected within the next year (expected by Q4 2010 to as late as Q2 2011), upon completion of the 18 month follow-up.
(Article Source: http://www.cancer.org/aspx/blog/Comments.aspx?id=130, Image Source: http://www.depmed.ualberta.ca/dca/)
Stay tuned later for more news on this potentially more cost effective treatment.